Advertisement

Psychopharmacology

, Volume 231, Issue 15, pp 2955–2965 | Cite as

High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression

  • Thorsten Mikoteit
  • Johannes Beck
  • Anne Eckert
  • Ulrich Hemmeter
  • Serge Brand
  • Roland Bischof
  • Edith Holsboer-Trachsler
  • Alexandra Delini-Stula
Original Investigation

Abstract

Rationale

Major depressive disorder has been associated with low serum levels of brain-derived neurotrophic factor (sBDNF), which is functionally involved in neuroplasticity. Although sBDNF levels tend to normalize following psychopathological improvement with antidepressant treatment, it is unclear how closely sBDNF changes are associated with treatment outcome.

Objectives

To examine whether baseline sBDNF or early changes in sBDNF are predictive of response to therapy.

Methods

Twenty-five patients with major depressive disorder underwent standardized treatment with duloxetine. Severity of depression, measured by the Hamilton Depression Rating Scale, and sBDNF were assessed at baseline, and after 1, 2, and 6 weeks of treatment. Therapy outcome after 6 weeks was defined as response (≥50 % reduction in baseline Hamilton Depression Rating score) and remission (Hamilton Depression Rating score <8). The predictive values for treatment outcome of baseline sBDNF, and early (i.e., ≤2 weeks) changes in sBDNF and Hamilton Depression Rating score were also assessed.

Results

At baseline, sBDNF correlated with Hamilton Depression Rating scores. Treatment response was associated with a higher baseline sBDNF concentration, and a greater Hamilton Depression Rating score reduction after 1 and 2 weeks. A greater early rise in sBDNF correlated with a decreased early Hamilton Depression Rating score reduction.

Conclusions

Even though higher baseline sBDNF levels are associated with more severe depression, they may reflect an increased capacity to respond to treatment. In contrast, changes in sBDNF over the full course of treatment are not associated with psychopathological improvement.

Keywords

Brain-derived neurotrophic factor (BDNF) Serum Depression Treatment outcome Early response Response Remission Antidepressants Serotonin norepinephrine reuptake inhibitor (SNRI) Duloxetine 

Notes

Acknowledgments

This study is an Investigator Initiated Study (ITT) financed by a special grant from Eli Lilly SA, Switzerland. The company had, however, no influence on either the designing or writing of the protocol of the study or analysis and interpretation of study results. The preparation of the manuscript for publication was not supported by the company. E. H. and A. D. are members of the Eli Lilly Advisory Board. A. D. has consulted for the company on various occasions and was involved in the preparation of paid expert reports and educational programs for GPs. No potential conflicts of interests exist for other authors. The authors thank Nick Emler (Surrey, UK) for proofreading the manuscript.

References

  1. Aydemir C, Yalcin ES, Aksaray S, Kisa C, Yildirim SG, Uzbay T, Goka E (2006) Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuropsychopharmacol Biol Psychiatry 30:1256–1260PubMedCrossRefGoogle Scholar
  2. Başterzi AD, Yazici K, Aslan E, Delialioğlu N, Taşdelen B, Tot Acar S, Yazici A (2009) Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 33:281–285PubMedCrossRefGoogle Scholar
  3. Berchtold NC, Kesslak JP, Pike CJ, Adlard PA, Cotman CW (2001) Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur J Neurosci 14:1992–2002PubMedCrossRefGoogle Scholar
  4. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M (2010) Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11:763–773PubMedCrossRefGoogle Scholar
  5. Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180PubMedCrossRefGoogle Scholar
  6. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, Elzinga BM, Voshaar RC (2011) Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 36:228–239PubMedCrossRefGoogle Scholar
  7. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880PubMedCrossRefGoogle Scholar
  8. Chan KL, Tong KY, Yip SP (2008) Relationship of serum brain-derived neurotrophic factor (BDNF) and health-related lifestyle in healthy human subjects. Neurosci Lett 447:124–128PubMedCrossRefGoogle Scholar
  9. Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, HillsdaleGoogle Scholar
  10. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O'Neill MJ, Zetterström TS (2004) Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 128:597–604PubMedCrossRefGoogle Scholar
  11. Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R (2013) Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry 46:54–58PubMedGoogle Scholar
  12. Dreimüller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadić A (2012) Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with major depression. Neuropharmacology 62:264–269PubMedCrossRefGoogle Scholar
  13. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127PubMedCrossRefGoogle Scholar
  14. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F (2005) Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51:234–238PubMedCrossRefGoogle Scholar
  15. Giese M, Unternährer E, Hüttig H, Beck J, Brand S, Calabrese P, Holsboer-Trachsler E, Eckert A (2013) BDNF: an indicator of insomnia? Mol Psychiatry. doi: 10.1038/mp.2013.10 PubMedCentralGoogle Scholar
  16. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S (2005) Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255:381–386PubMedCrossRefGoogle Scholar
  17. Haghighi M, Salehi I, Erfani P, Jahangard L, Bajoghli H, Holsboer-Trachsler E, Brand S (2013) Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 47:908–915PubMedCrossRefGoogle Scholar
  18. Hallbook F (1999) Evolution of the vertebrate neurotrophin and Trk receptor gene families. Curr Opin Neurobiol 9:616–621PubMedCrossRefGoogle Scholar
  19. Hellweg R, Ziegenhorn A, Heuser I, Deuschle M (2008) Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 41:66–71PubMedCrossRefGoogle Scholar
  20. Huang TL, Lee CT, Liu YL (2008) Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 42:521–525PubMedCrossRefGoogle Scholar
  21. Jacobsen JP, Mørk A (2004) The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024:183–192PubMedCrossRefGoogle Scholar
  22. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM (2002) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109:143–148PubMedCrossRefGoogle Scholar
  23. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G (2005) Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 57:1068–1072PubMedCrossRefGoogle Scholar
  24. Khundakar AA, Zetterström TS (2006) Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Res 1106:12–20PubMedCrossRefGoogle Scholar
  25. Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, Lee SW, Yoon D, Han C, Kim DJ, Choi SH (2007) Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 31:78–85PubMedCrossRefGoogle Scholar
  26. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Mendlewicz J, Noro M, Montgomery S, Oswald P, Snyder L, Zohar J, Souery D (2011) Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26:1–10PubMedCrossRefGoogle Scholar
  27. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD (2007) Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 555:115–121PubMedCrossRefGoogle Scholar
  28. Larsen MH, Hay-Schmidt A, Rønn LC, Mikkelsen JD (2008) Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur J Pharmacol 578:114–122PubMedCrossRefGoogle Scholar
  29. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C (2010) Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 44:808–816PubMedCrossRefGoogle Scholar
  30. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetke CZ, Schuff-Werner P, Virchow JC (2005) The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26:115–123PubMedCrossRefGoogle Scholar
  31. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43:247–254Google Scholar
  32. Musazzi L, Cattaneo A, Tardito D, Barbon A, Gennarelli M, Barlati S, Racagni G, Popoli M (2009) Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neurosci 10:48PubMedCentralPubMedCrossRefGoogle Scholar
  33. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 37:1553–1561PubMedCrossRefGoogle Scholar
  34. Pluchino N, Russo M, Santoro AN, Litta P, Cela V, Genazzani AR (2013) Steroid hormones and BDNF. Neuroscience 239:271–279PubMedCrossRefGoogle Scholar
  35. Schmidt-Kassow M, Schädle S, Otterbein S, Thiel C, Doehring A, Lötsch J, Kaiser J (2012) Kinetics of serum brain-derived neurotrophic factor following low-intensity versus high-intensity exercise in men and women. Neuroreport 23:889–893PubMedCrossRefGoogle Scholar
  36. Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527–532PubMedCentralPubMedCrossRefGoogle Scholar
  37. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70–75PubMedCrossRefGoogle Scholar
  38. Stassen HH, Delini-Stula A, Angst J (1993) Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 3:127–135PubMedCrossRefGoogle Scholar
  39. Stassen HH, Angst J, Delini-Stula A (1996) Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 29:87–96PubMedCrossRefGoogle Scholar
  40. Stassen HH, Angst J, Delini-Stula A (1997) Delayed onset of action of antidepressant drugs? Survey of recent results. Eur Psychiatry 12:166–176PubMedCrossRefGoogle Scholar
  41. Tadić A, Wagner S, Schlicht KF, Peetz D, Borysenko L, Dreimüller N, Hiemke C, Lieb K (2011) The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 35:415–420PubMedCrossRefGoogle Scholar
  42. Tang SW, Chu E, Hui T, Helmeste D, Law C (2008) Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett 431:62–65PubMedCrossRefGoogle Scholar
  43. Vanevski F, Xu B (2013) Molecular and neural bases underlying roles of BDNF in the control of body weight. Front Neurosci 7:37. doi: 10.3389/fnins.2013.00037 PubMedCentralPubMedCrossRefGoogle Scholar
  44. Watanabe K, Hashimoto E, Ukai W, Ishii T, Yoshinaga T, Ono T, Tateno M, Watanabe I, Shirasaka T, Saito S, Saito T (2010) Effect of antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats. Prog Neuropsychopharmacol Biol Psychiatry 34:1450–1454PubMedCrossRefGoogle Scholar
  45. World Health Organization (1994) ICD-10 classification of mental and behavioural disorders with glossary and diagnostic criteria for research ICD10:DCR-10. Churchill Livingstone, EdinburghGoogle Scholar
  46. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J (2007) Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31:1034–1037PubMedCrossRefGoogle Scholar
  47. Ziegenhorn AA, Schulte-Herbrüggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, Lang UE, Steinhagen-Thiessen E, Schaub RT, Hellweg R (2007) Serum neurotrophins—a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 28:1436–1445PubMedCrossRefGoogle Scholar
  48. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF (2010) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20:535–544PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Thorsten Mikoteit
    • 1
  • Johannes Beck
    • 1
  • Anne Eckert
    • 2
  • Ulrich Hemmeter
    • 3
  • Serge Brand
    • 1
  • Roland Bischof
    • 4
  • Edith Holsboer-Trachsler
    • 1
  • Alexandra Delini-Stula
    • 4
  1. 1.Center for Affective, Stress and Sleep Disorders (ZASS)Psychiatric Clinics of the University of BaselBaselSwitzerland
  2. 2.Neurobiology Laboratory for Brain Aging and Mental HealthPsychiatric Clinics of the University of BaselBaselSwitzerland
  3. 3.Center of Education and Research (COEUR)Psychiatric Service Canton of St. GallenWilSwitzerland
  4. 4.ADI International Institute for Advancement of Drug Development GmbHBaselSwitzerland

Personalised recommendations